Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
Schafer ES, Rushing T, Crews KR, Annesley C, Colace SI, Kaiser N, Pommert L, Ramsey LB, Sabnis HS, Wong K, Chang BH, Cooper TM, Shah NN, Rheingold SR, Place AE, Chi YY, Bhojwani D, Wayne AS, Bernhardt MB. Schafer ES, et al. Among authors: chi yy. J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165. J Natl Cancer Inst. 2024. PMID: 38964343
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).
Tasian SK, Silverman LB, Whitlock JA, Sposto R, Loftus JP, Schafer ES, Schultz KR, Hutchinson RJ, Gaynon PS, Orgel E, Bateman CM, Cooper TM, Laetsch TW, Sulis ML, Chi YY, Malvar J, Wayne AS, Rheingold SR. Tasian SK, et al. Among authors: chi yy. Haematologica. 2022 Oct 1;107(10):2295-2303. doi: 10.3324/haematol.2021.279520. Haematologica. 2022. PMID: 35112552 Free PMC article. Clinical Trial.
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Pommert L, et al. Among authors: chi yy. Am J Hematol. 2022 May;97(5):613-622. doi: 10.1002/ajh.26510. Epub 2022 Mar 8. Am J Hematol. 2022. PMID: 35180323 Free PMC article. Clinical Trial.
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li HT, Liang G, Leong R, Brown PA, Kaplan J, Schafer ES, Slone T, Pauly M, Chang BH, Stieglitz E, Wayne AS, Hijiya N, Bhojwani D. Verma A, et al. Among authors: chi yy. Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496. Cancers (Basel). 2024. PMID: 38339248 Free PMC article.
Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial.
Orgel E, Knight KR, Chi YY, Malvar J, Rushing T, Mena V, Eisenberg LS, Rassekh SR, Ross CJD, Scott EN, Neely M, Neuwelt EA, Muldoon LL, Freyer DR. Orgel E, et al. Among authors: chi yy. Clin Cancer Res. 2023 Jul 5;29(13):2410-2418. doi: 10.1158/1078-0432.CCR-23-0252. Clin Cancer Res. 2023. PMID: 37134194 Free PMC article. Clinical Trial.
Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Li H, Sisoudiya SD, Martin-Giacalone BA, Khayat MM, Dugan-Perez S, Marquez-Do DA, Scheurer ME, Muzny D, Boerwinkle E, Gibbs RA, Chi YY, Barkauskas DA, Lo T, Hall D, Stewart DR, Schiffman JD, Skapek SX, Hawkins DS, Plon SE, Sabo A, Lupo PJ. Li H, et al. Among authors: chi yy. J Natl Cancer Inst. 2021 Jul 1;113(7):875-883. doi: 10.1093/jnci/djaa204. J Natl Cancer Inst. 2021. PMID: 33372952 Free PMC article.
Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM, Chi YY, Venkatramani R, Li M, Arnold MA, Dasgupta R, Hiniker SM, Hawkins DS, Mascarenhas L. Heske CM, et al. Among authors: chi yy. Cancer. 2021 Mar 15;127(6):946-956. doi: 10.1002/cncr.33334. Epub 2020 Nov 20. Cancer. 2021. PMID: 33216382 Free PMC article.
Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534).
Chintagumpala MM, Perlman EJ, Tornwall B, Chi YY, Kim Y, Hoffer FA, Kalapurakal JA, Warwick AB, Shamberger RC, Khanna G, Hamilton TE, Gow KW, Paulino AC, Gratias EJ, Mullen EA, Geller JI, Fernandez CV, Ritchey ML, Grundy PE, Dome JS, Ehrlich PF. Chintagumpala MM, et al. Among authors: chi yy. Cancer. 2022 Jul 1;128(13):2493-2503. doi: 10.1002/cncr.34219. Epub 2022 Apr 5. Cancer. 2022. PMID: 35383900 Free PMC article.
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S, Weigel BJ, Chi YY, Tian J, Anderson JR, Parham DM, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Spunt SL, Meyer WH, Hawkins DS. Malempati S, et al. Among authors: chi yy. Cancer. 2019 Jan 15;125(2):290-297. doi: 10.1002/cncr.31770. Epub 2018 Oct 23. Cancer. 2019. PMID: 30351457 Free PMC article. Clinical Trial.
175 results